Capgemini Leads in Revolutionizing Rare Disease Care with Next-Gen CRMs
Life sciences companies tackling rare diseases face unique challenges in managing patient care. Traditional CRM systems fall short, but next-gen CRMs offer tailored solutions. Capgemini is at the forefront, helping these companies build therapeutic area-specific CRM strategies for Gen Z and Gen X patients.
Next-gen CRMs can revolutionize rare disease care. They can inform and personalize education campaigns for healthcare professionals and patients, keeping them updated on the latest treatments. Moreover, these systems enable new care models like value-based care and hyper-personalized treatments such as cell and gene therapy.
End-to-end CRM connectivity allows for real-time personalization of care, guiding each stakeholder step-by-step. By integrating both clinical and social data, next-gen CRMs provide a 360-degree view of each patient, connecting the patient journey seamlessly. This is crucial as there is no standard path to care for rare disease patients, requiring complex coordination across multiple stakeholders and systems.
Capgemini can help life sciences companies build and execute a therapeutic area-specific CRM strategy for rare diseases. Unlike traditional engagement models and tools, next-gen CRMs can unify disparate information, giving healthcare providers real-time visibility into the patient journey.
With an estimated 300 million people worldwide living with one of 6,000 recognized rare conditions, the need for effective management is clear. Next-gen CRMs, with their ability to personalize care and connect stakeholders, are a game-changer for Gen Z and Gen X patients. Companies like Capgemini are leading the way in implementing these systems, helping life sciences companies navigate the complex landscape of rare disease care using CareCredit.
